Skip to main content
Top

Cancer and Metastasis Reviews

1997 - 2025
Volumes
95
Issues
Chevron right icon
Issue 1/2025
Latest issue

About this journal

The transformation of biology from a descriptive, phenomenological discipline to one in which the regulatory principles are understood and predictably manipulated brings new opportunities to the study of cancer and the search for effective therapeutic modalities. Cancer and Metastasis Reviews offers a forum for critical review and discussion of these challenges.


Each issue presents five to seven different contributions on a single theme or topic, with an introductory essay from a distinguished individual in the field. Special emphasis is placed on subjects of relevance to the molecular and cellular biology of cancer metastasis and tumor progression, as well as to the treatment of metastatic disease. Occasional issues will be devoted to an in-depth clinical and biological analysis of a particular type of cancer.


The journal also reviews important recent developments in the biology and treatment of malignant disease, and highlights promising new directions.

Metadata
Title
Cancer and Metastasis Reviews
Coverage
Volume 16/1997 - Volume 44/2025
Publisher
Springer US
Electronic ISSN
1573-7233
Print ISSN
0167-7659
Journal ID
10555
DOI
https://doi.org/10.1007/10555.1573-7233

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now